BioLineRx (BLRX) Invested Capital (2021 - 2025)

BioLineRx has reported Invested Capital over the past 5 years, most recently at $22.7 million for Q4 2025.

  • Quarterly results put Invested Capital at $22.7 million for Q4 2025, up 26.39% from a year ago — trailing twelve months through Dec 2025 was $22.7 million (up 26.39% YoY), and the annual figure for FY2025 was $22.7 million, up 26.39%.
  • Invested Capital for Q4 2025 was $22.7 million at BioLineRx, up from $17.9 million in the prior quarter.
  • Over the last five years, Invested Capital for BLRX hit a ceiling of $22.7 million in Q4 2025 and a floor of $1.5 million in Q4 2022.
  • Median Invested Capital over the past 5 years was $3.1 million (2023), compared with a mean of $9.6 million.
  • Biggest five-year swings in Invested Capital: crashed 44.07% in 2022 and later skyrocketed 470.43% in 2024.
  • BioLineRx's Invested Capital stood at $2.8 million in 2021, then tumbled by 44.07% to $1.5 million in 2022, then skyrocketed by 103.96% to $3.1 million in 2023, then skyrocketed by 470.43% to $17.9 million in 2024, then rose by 26.39% to $22.7 million in 2025.
  • The last three reported values for Invested Capital were $22.7 million (Q4 2025), $17.9 million (Q4 2024), and $3.1 million (Q4 2023) per Business Quant data.